Vaccine Adjuvant Market Size, Share, Growth by 2030

The vaccine adjuvants market is projected to expand from US$ 2,482.39 million in 2022 to US$ 6,931.55 million by 2028, reflecting a compound annual growth rate (CAGR) of 13.7% during this period.

The growth of the vaccine adjuvant market is significantly influenced by advancements in adjuvant research and collaborative initiatives aimed at product launches, which present numerous opportunities for market expansion.

An adjuvant is an additive in vaccine formulations that enhances the immune response in individuals receiving the vaccine. The increasing frequency of infectious disease outbreaks and pandemics, along with the regulatory approvals for veterinary vaccine adjuvants, are primary factors driving the market's growth. Conversely, challenges such as product recalls and adverse reactions can hinder the progress of the vaccine adjuvant market.

Growth Drivers

Support for advancements in adjuvant research and collaborative product launches is creating significant opportunities within the vaccine adjuvant sector.

The National Institute of Allergy and Infectious Diseases (NIAID) plays a pivotal role in the discovery, development, and characterization of new vaccine adjuvants. This institute is essential in enhancing the effectiveness of existing vaccines, creating new or improved vaccines for both current and emerging infectious diseases, and developing vaccines for allergies, autoimmune disorders, and cancer. NIAID's vaccine adjuvant research program aims to create a range of adjuvants that can be paired with antigens to maximize vaccine efficacy. To promote collaboration between NIAID-supported researchers and the wider scientific community, NIAID launched the Vaccine Adjuvant Compendium (VAC) in 2020. This online resource provides detailed information on adjuvant characteristics, assisting vaccine developers in selecting appropriate adjuvants for their specific diseases.

Companies in the vaccine sector, such as SK Biosciences and GSK, are scaling up adjuvant production to meet global demand, employing growth strategies that include partnerships. For example, in April 2022, SK Biosciences and GSK announced the submission of a biological license application for SKYCovione to the Korean Ministry of Food and Drug Safety (KMFDS) after obtaining favorable results from Phase 3 clinical trials. The backing from various governmental bodies to promote vaccine adjuvant research and development, along with collaborations among leading manufacturers and innovative product launches through these partnerships, is expected to create lucrative opportunities for the vaccine adjuvants market in the coming years.

In 2022, the mineral salt adjuvant segment dominated the vaccine adjuvant market by adjuvant class. The emulsion adjuvant segment is anticipated to experience the highest CAGR of 14.6% during the forecast period. Mineral salts, including insoluble aluminum salts and calcium phosphates, are commonly utilized as adjuvants in vaccine formulations. Aluminum salt-based adjuvants are known to promote early and long-lasting protective immunity. The US Food and Drug Administration (FDA) regulates aluminum adjuvants used in human vaccines, ensuring that small quantities of aluminum are included to enhance immunogenicity compared to the antigen alone. The formulation of mineral salt adjuvants at the site of inflammation triggers a rapid immune response by releasing pro-inflammatory cytokines, thus supporting the growth of the vaccine adjuvants market.

In 2022, North America accounted for the largest share of the global vaccine adjuvant market. The Asia Pacific region is expected to exhibit the highest CAGR from 2022 to 2030. The swift approval processes for vaccine adjuvants in North America significantly contribute to market growth. Furthermore, the presence of leading manufacturers in the region bolsters overall market expansion.

The expedited approval processes in the US are advantageous for the vaccine adjuvants market. For instance, in May 2023, GlaxoSmithKline (GSK) received FDA approval for Arexvy, an adjuvanted vaccine for respiratory syncytial virus (RSV), aimed at preventing lower respiratory tract disease (LRTD) in older adults. This marked Arexvy as the first FDA-approved RSV vaccine for this demographic. Additionally, in October 2022, Novavax, Inc. obtained Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, designated as a booster for adult patients.

Industry Developments and Future Opportunities

Several strategic initiatives by key players in the vaccine adjuvant market are highlighted below:

- In April 2022, GSK plc and SK Bioscience submitted a biologics license application for SKYCovione, a recombinant protein-based, adjuvanted COVID-19 vaccine candidate that incorporates GSK's pandemic adjuvant. This application was made to the Korean Ministry of Food and Drug Safety following positive Phase III clinical trial results.

- In November 2021, Seppic introduced MONTANIDE GEL P PR, an aqueous adjuvant based on polymeric technology specifically designed for avian injectable vaccines, addressing the need for safety in the avian market. MONTANIDE GEL P PR is notably stable and can withstand destabilizing antigenic media commonly used in avian vaccines.

- In October 2023, SPI Pharma Inc. and Q-Vant Biosciences Inc. announced a partnership that merges Q-Vant's expertise in sustainable saponin extraction technology with SPI's extensive reach and service capabilities in the pharmaceutical sector. This collaboration includes investments to enhance Q-Vant's proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to promote the global adoption of their saponin adjuvants for both veterinary and human vaccine formulations.

- In January 2023, the Korean Ministry of Food and Drug Safety (KMFDS) granted SK Bioscience enhanced manufacturing and marketing authorization for NuvaxovidTM, allowing its administration as a booster for adults aged 18 and older.

Vaccine Adjuvant Market Size, Share, Growth by 2030

Growth Drivers

Industry Developments and Future Opportunities

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

Related Reports